GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Applied Genetic Technologies Corp (NAS:AGTC) » Definitions » Interest Coverage

Applied Genetic Technologies (Applied Genetic Technologies) Interest Coverage : 0 (At Loss) (As of Sep. 2022)


View and export this data going back to 2014. Start your Free Trial

What is Applied Genetic Technologies Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Applied Genetic Technologies's Operating Income for the three months ended in Sep. 2022 was $-17.34 Mil. Applied Genetic Technologies's Interest Expense for the three months ended in Sep. 2022 was $-0.66 Mil. did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is.

The historical rank and industry rank for Applied Genetic Technologies's Interest Coverage or its related term are showing as below:


AGTC's Interest Coverage is not ranked *
in the Biotechnology industry.
Industry Median: 127.155
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


Applied Genetic Technologies Interest Coverage Historical Data

The historical data trend for Applied Genetic Technologies's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Applied Genetic Technologies Interest Coverage Chart

Applied Genetic Technologies Annual Data
Trend Jun13 Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22
Interest Coverage
Get a 7-Day Free Trial Premium Member Only Premium Member Only No Debt No Debt - - -

Applied Genetic Technologies Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Interest Coverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Applied Genetic Technologies's Interest Coverage

For the Biotechnology subindustry, Applied Genetic Technologies's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Applied Genetic Technologies's Interest Coverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Applied Genetic Technologies's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Applied Genetic Technologies's Interest Coverage falls into.



Applied Genetic Technologies Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Applied Genetic Technologies's Interest Coverage for the fiscal year that ended in Jun. 2022 is calculated as

Here, for the fiscal year that ended in Jun. 2022, Applied Genetic Technologies's Interest Expense was $-2.67 Mil. Its Operating Income was $-66.18 Mil. And its Long-Term Debt & Capital Lease Obligation was $11.90 Mil.

Applied Genetic Technologies did not have earnings to cover the interest expense.

Applied Genetic Technologies's Interest Coverage for the quarter that ended in Sep. 2022 is calculated as

Here, for the three months ended in Sep. 2022, Applied Genetic Technologies's Interest Expense was $-0.66 Mil. Its Operating Income was $-17.34 Mil. And its Long-Term Debt & Capital Lease Obligation was $9.34 Mil.

Applied Genetic Technologies did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.


Applied Genetic Technologies  (NAS:AGTC) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


Applied Genetic Technologies Interest Coverage Related Terms

Thank you for viewing the detailed overview of Applied Genetic Technologies's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Applied Genetic Technologies (Applied Genetic Technologies) Business Description

Traded in Other Exchanges
N/A
Address
14193 NW 119th Terrace, Suite 10, Alachua, FL, USA, 32615
Applied Genetic Technologies Corp is a clinical-stage biotechnology company that uses a proprietary gene therapy platform to develop transformational genetic therapies for patients suffering from rare and debilitating diseases. Its initial focus is in the field of ophthalmology, where it has active clinical trials in X-linked retinitis pigmentosa, achromatopsia (ACHM CNGB3 and ACHM CNGA3), and X-linked retinoschisis. In addition to its clinical trials, company has preclinical programs in optogenetics, adrenoleukodystrophy, which is a disease of the central nervous system, other ophthalmology, and otology indications. The optogenetics program is being developed in collaboration with Bionic Sight.
Executives
Susan Schneider officer: Chief Medical Officer C/O APPLIED GENETIC TECHNOLOGIES CORP., 14193 NW 119TH TERRACE, SUITE 10, ALACHUA FL 32615
Jonathan I Lieber officer: Chief Financial Officer C/O HISTOGENICS CORPORATION, 830 WINTER STREET #3, WALTHAM MA 02451
Stephen W Potter officer: See Remarks 7015 ALBERT EINSTEIN DR, COLUMBIA MD 21046
Gerald Anthony Reynolds officer: Chief Accounting Officer C/O APPLIED GENETIC TECHNOLOGIES CORP., 14193 NW 119TH TERRACE, SUITE 10, ALACHUA FL 32615
Susan B. Washer director, officer: President and CEO C/O APPLIED GENETIC TECHNOLOGIES CORP., 11801 RESEARCH DRIVE, SUITE D, ALACHUA FL 32615
Hope Doyley-gay officer: General Counsel C/O APPLIED GENETIC TECHNOLOGIES CORP., 14193 NW 119TH TERRACE, SUITE 10, ALACHUA FL 32615
Abraham Scaria officer: Chief Scientific Officer C/O APPLIED GENETIC TECHNOLOGIES CORP, 14193 NW 119TH TERRACE, SUITE 10, ALACHUA FL 32615
Yehia Hashad director C/O APPLIED GENETIC TECHNOLOGIES CORP., 14193 NW 119TH TERRACE, SUITE 10, ALACHUA FL 32615
Robinson James A. Jr. director 852 WINTER STREET, WALTHAM MA 02451
William Aliski director C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Krol Patrick Johan Hendrik 10 percent owner GUSTAV MAHLERPLEIN 3, AMSTERDAM P7 1082 MS
Privium Fund Management B.v. 10 percent owner GUSTAV MAHLERPLEIN 3, AMSTERDAM P7 1082 MS
Aescap 2.0 Stichting 10 percent owner GUSTAV MAHLERPLEIN 3, AMSTERDAM P7 1082 MS
Inspirational Visions B.v. 10 percent owner C/O PROQR THERAPEUTICS N.V., ZERNIKEDREEF 9, 2333 CK LEIDEN P7 2333
Brian Krex officer: General Counsel C/O AGTC, 14193 NW 119TH TERRACE, SUITE #10, ALACHUA FL 32615

Applied Genetic Technologies (Applied Genetic Technologies) Headlines